Advanced ovarian cancer in the elderly: Results of consecutive trials with cisplatin-based chemotherapy

Silvana Chiara, Rita Lionetto, Maura Vincenti, Milena Bruzzone, Maria Teresa Nobile, Angiolo Gadducci, Flavio Carnino, Riccardo Rosso, PierFranco Conte

Research output: Contribution to journalArticlepeer-review

Abstract

From 1982 through 1996, 547 untreated advanced ovarian cancer patients were entered onto Gruppo Oncologico Nord-Ovest (GONO) consecutive randomized trials including cisplatin-based chemotherapy. End points of analysis included the influence of age on prognosis, toxicity, clinical/surgical response rates, progression-free survival and survival. Of the entire study group, 116 patients were 65 years of age or older at diagnosis. WHO main toxicity (any grade) consisted of: emesis (93% of patients), myelotoxicity (leukopenia in 52%, anemia in 51% and thrombocytopenia in 17% of patients), nephrotoxicity in 13% of patients and neurotoxicity in 10% of patients. No significant difference in toxicity was evident between patients ≥ or 65 years per se was not a negative prognostic factor.

Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume37
Issue number1
DOIs
Publication statusPublished - 2001

Keywords

  • Chemotherapy
  • Cisplatin
  • Elderly
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Advanced ovarian cancer in the elderly: Results of consecutive trials with cisplatin-based chemotherapy'. Together they form a unique fingerprint.

Cite this